Tags

Type your tag names separated by a space and hit enter

An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
Am J Manag Care. 2000 Mar; 6(3):381-9.AJ

Abstract

OBJECTIVE

To examine treatment costs of community-acquired pneumonia (CAP) in adult outpatients given oral (p.o.) levofloxacin or cefuroxime axetil as initial therapy.

STUDY DESIGN

Patients with a primary diagnosis of CAP were enrolled in a multicenter, prospective, randomized, open-label, active-controlled Phase III clinical trial. Both inpatients and outpatients were assigned to 1 of 2 treatment groups: (1) intravenous (i.v.) or p.o. levofloxacin; or (2) i.v. ceftriaxone and/or p.o. cefuroxime axetil.

METHODS

To make legitimate and meaningful cost comparisons between similar types of patients receiving drugs via the same route of administration (i.e., orally), this outpatient economic study examined the resource utilization of the 211 patients enrolled as outpatients who received oral formulations as initial treatment (levofloxacin, 103 patients; cefuroxime axetil, 108 patients). Resource utilization data and clinical trial data were collected concurrently. To generate cost estimates, Medicare cost estimates for resources were multiplied by the resource units used by patients in each treatment arm.

RESULTS

Cost estimates indicated a total cost difference that favored the levofloxacin group (base case: $169; sensitivity analysis: $223 [P = .008]). The results for the base case were not significant (P = .094). In addition, within the cost categories, there was a statistically significant study drug cost differential favoring levofloxacin ($86; P = .0001 for both the base case and sensitivity analysis).

CONCLUSION

Oral levofloxacin is less costly than oral cefuroxime axetil in the outpatient treatment of adults with CAP.

Authors+Show Affiliations

ICOM Health Care Economics, Johnson & Johnson, Raritan, NJ 08869-0602, USA. brittenh@prius.jnj.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10977438

Citation

Rittenhouse, B E., et al. "An Economic Evaluation of Levofloxacin Versus Cefuroxime Axetil in the Outpatient Treatment of Adults With Community-acquired Pneumonia." The American Journal of Managed Care, vol. 6, no. 3, 2000, pp. 381-9.
Rittenhouse BE, Stinnett AA, Dulisse B, et al. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am J Manag Care. 2000;6(3):381-9.
Rittenhouse, B. E., Stinnett, A. A., Dulisse, B., Henke, C. J., Potter, L., Parasuraman, B., Martens, L. L., Williams, R. R., & Kojak, C. (2000). An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. The American Journal of Managed Care, 6(3), 381-9.
Rittenhouse BE, et al. An Economic Evaluation of Levofloxacin Versus Cefuroxime Axetil in the Outpatient Treatment of Adults With Community-acquired Pneumonia. Am J Manag Care. 2000;6(3):381-9. PubMed PMID: 10977438.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. AU - Rittenhouse,B E, AU - Stinnett,A A, AU - Dulisse,B, AU - Henke,C J, AU - Potter,L, AU - Parasuraman,B, AU - Martens,L L, AU - Williams,R R, AU - Kojak,C, PY - 2000/9/8/pubmed PY - 2000/9/8/medline PY - 2000/9/8/entrez SP - 381 EP - 9 JF - The American journal of managed care JO - Am J Manag Care VL - 6 IS - 3 N2 - OBJECTIVE: To examine treatment costs of community-acquired pneumonia (CAP) in adult outpatients given oral (p.o.) levofloxacin or cefuroxime axetil as initial therapy. STUDY DESIGN: Patients with a primary diagnosis of CAP were enrolled in a multicenter, prospective, randomized, open-label, active-controlled Phase III clinical trial. Both inpatients and outpatients were assigned to 1 of 2 treatment groups: (1) intravenous (i.v.) or p.o. levofloxacin; or (2) i.v. ceftriaxone and/or p.o. cefuroxime axetil. METHODS: To make legitimate and meaningful cost comparisons between similar types of patients receiving drugs via the same route of administration (i.e., orally), this outpatient economic study examined the resource utilization of the 211 patients enrolled as outpatients who received oral formulations as initial treatment (levofloxacin, 103 patients; cefuroxime axetil, 108 patients). Resource utilization data and clinical trial data were collected concurrently. To generate cost estimates, Medicare cost estimates for resources were multiplied by the resource units used by patients in each treatment arm. RESULTS: Cost estimates indicated a total cost difference that favored the levofloxacin group (base case: $169; sensitivity analysis: $223 [P = .008]). The results for the base case were not significant (P = .094). In addition, within the cost categories, there was a statistically significant study drug cost differential favoring levofloxacin ($86; P = .0001 for both the base case and sensitivity analysis). CONCLUSION: Oral levofloxacin is less costly than oral cefuroxime axetil in the outpatient treatment of adults with CAP. SN - 1088-0224 UR - https://www.unboundmedicine.com/medline/citation/10977438/An_economic_evaluation_of_levofloxacin_versus_cefuroxime_axetil_in_the_outpatient_treatment_of_adults_with_community_acquired_pneumonia_ L2 - https://www.ajmc.com/pubMed.php?pii=1007 DB - PRIME DP - Unbound Medicine ER -